Estimating the impact of multiple immunization products on medically-attended respiratory syncytial virus (RSV) infections in infants

BACKGROUND: Palivizumab, a monoclonal antibody and the only licensed immunization product for preventing respiratory syncytial virus (RSV) infection, is recommended for children with certain high-risk conditions. Other antibody products and maternal vaccines targeting young infants are in clinical d...

Descripción completa

Detalles Bibliográficos
Autores principales: Rainisch, Gabriel, Adhikari, Bishwa, Meltzer, Martin I., Langley, Gayle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029767/
https://www.ncbi.nlm.nih.gov/pubmed/31740097
http://dx.doi.org/10.1016/j.vaccine.2019.10.023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7029767/
https://www.ncbi.nlm.nih.gov/pubmed/31740097
http://dx.doi.org/10.1016/j.vaccine.2019.10.023

Ejemplares similares